The recently published crystal structure of the external domains of αVβ3 confirms the prediction that the aminoterminal portion of αV, which shares 40% homology with αIIb, folds into a β-propeller structure and that the 4 calcium-binding domains are positioned on the bottom of the propeller. To gain insight into the role of the calcium-binding domains in αIIb biogenesis, we characterized mutations in the second and third calcium-binding domains of αIIb in 2 patients with Glanzmann thrombasthenia. One patient inherited a Val298Phe mutation in the second domain, and the other patient inherited an Ile374Thr mutation in the third domain. Mammalian cell expression studies were performed with normal and mutant αIIb and β3 cDNA constructs. By flow cytometry, expression of αIIb Val298Phe/β3 in transfected cells was 28% of control, and expression of αIIbIle374Thr/β3 was 11% of control. Pulse-chase analyses showed that both mutant pro-αIIb subunits are retained in the endoplasmic reticulum and degraded. Mutagenesis studies of the Val298 and Ile374 residues showed that these highly conserved, branch-chained hydrophobic residues are essential at these positions and that biogenesis and expression of αIIbβ3 is dramatically affected by structural variations in these regions of the calcium-binding domains. Energy calculations derived from a new model of the αIIb β-propeller indicate that these mutations interfere with calcium binding. These data suggest that the αIIb calcium-binding domains play a key structural role in the β-propeller, and that the structural integrity of the calcium-binding domains is critical for integrin biogenesis.

The platelet glycoprotein (GP) IIb/IIIa (integrin αIIbβ3) receptor plays a key role in platelet aggregation. Inherited abnormalities of αIIbβ3 result in Glanzmann thrombasthenia, a variably severe mucocutaneous bleeding disorder.1,2 Conversely, inhibition of αIIbβ3 with antagonist drugs can prevent the thrombotic complications of percutaneous coronary interventions and acute coronary syndromes.3 

Mutations in either αIIb or β3 can result in Glanzmann thrombasthenia because the subunits must form a calcium-dependent complex for normal biogenesis and surface expression.4-6The αIIb subunit contains 4 calcium-binding domains, and mutations within or adjacent to the first and fourth domains, as well as between the second and third domains, have been reported to disrupt αIIbβ3 biogenesis by preventing receptor transport from the endoplasmic reticulum to the Golgi.7-11 

The recent publication of the crystal structure of the external domains of αVβ3 confirmed the prediction of Springer, based on computer modeling, that the amino terminus of αV folds into a 7-bladed β-propeller.12,13 The 40% sequence homology between αIIb and αV makes it likely that these integrin α-subunit siblings share the same basic structural elements. Each blade is composed of 4 β strands, which are connected by loops extending either above or below the plane of the propeller. The 4 calcium-binding domains are located in loops extending below propeller blades 4 to 7. The calcium-binding domains were originally described as being similar to EF hand structures, but more recent data from computer modeling and the crystallographic structure of αVβ3 indicate that the domains are β-hairpin loops.12-15 This has structural significance in that β-hairpin turns can play an important role in the initial folding of complex β structures.16 

In the present study, we describe data on 2 patients with Glanzmann thrombasthenia. One has a mutation in the second calcium-binding domain of αIIb, and the other has a mutation in the third calcium-binding domain. Both of these mutations (Val298Phe and Ile374Thr) are shown to be at key structural residues within the calcium-binding domains, and both interfere with αIIbβ3 biogenesis, thus potentially linking these phenomena. In fact, molecular modeling simulations indicate that both mutations interfere with calcium coordination and thus suggest that structurally intact calcium-binding domains are essential for αIIbβ3 biogenesis, heterodimer stability, and surface expression.

Case reports

Patient M was diagnosed as having Glanzmann thrombasthenia at 1 year of age based on typical laboratory findings and clinical history.17 Neither of his parents had any bleeding symptoms and there was no family history of bleeding. His parents originated from Puerto Rico and Canada, and there was no known consanguinity. Patient C was diagnosed as having Glanzmann thrombasthenia at 8 years of age based on typical laboratory findings and clinical history. His family history is significant for his father and his 2 siblings having bleeding symptoms, whereas his mother is asymptomatic. His paternal aunt and her child also had bleeding symptoms. The mother's family originated from Sicily and the father's from Naples. There was no known consanguinity. Approval for this study was obtained from the Institutional Review Boards of Mount Sinai School of Medicine, Cornell Medical Center, and University of Massachusetts Medical School; informed consent was provided according to the Declaration of Helsinki.

Surface expression of platelet glycoprotein (GP) Ib, αIIbβ3, and αVβ3 receptors

Platelet preparation and quantitative assessment of surface receptors by radiolabeled antibody binding was performed as previously described.18 Platelet surface GPIb was assessed by the binding of the murine monoclonal antibody (mAb) 6D119; αIIbβ3 was assessed by the binding of the complex-dependent murine mAb 10E520 and the Fab fragment of the mouse/human chimeric mAb 7E321,22 (which also reacts with αVβ3); and αVβ3 was assessed by the binding of the murine mAb LM60923 (provided by Dr D. Cheresh, Scripps Institute, La Jolla, CA).

Immunoblot analyses

Lysates of platelets and transfected cells were prepared as previously described.18,24,25 Immunoblot analyses of solubilized platelet and transfected cell proteins were performed by separating the proteins by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then electrotransferring them onto polyvinylidene difluoride (PVDF) membranes (Millipore, Burlington, MA), as previously described.18,24 The membranes were then incubated with a murine mAb specific for the heavy chain of mature αIIb, PMI-126,27 (provided by Dr M. Ginsberg, Scripps Institute), or a murine mAb specific for β3, 7H2.28Secondary labeling was performed using either a gold-conjugated antimouse IgG antibody with enhancement of the gold stain using a silver reagent (AuroProbe Forte kit, Amersham Pharmacia Biotech, Piscataway, NJ), or using a horseradish peroxidase (HRP)–conjugated rabbit antimouse κ light chain–specific antibody (Jackson Immunoresearch Laboratories, West Grove, PA).

DNA sequence analysis

gDNA was isolated from whole blood using the Puregene system (Gentra Systems, Minneapolis, MN), per the manufacturer's instructions. Oligonucleotide primers (Operon Technologies, Alameda, CA) were designed for polymerase chain reaction (PCR) amplification of one or more exons; one primer of each set was biotinylated for the purification of ssDNA for sequence analysis. The primers used for PCR and sequence analyses of αIIb are listed in Tables1 and 2. PCR amplification of the exons encoding αIIb was performed by adding about 100 ng gDNA, 0.2 μM biotinylated primer, 0.6 μM nonbiotinylated primer, 0.2 mM deoxyribonucleoside triphosphate (dNTP), 1.5 mM MgCl2, and 1.5 U Taq DNA polymerase (AmpliTaq; PE Applied Biosystems, Foster City, CA) to buffer (50 mM KCl, 10 mM Tris [tris(hydroxymethyl)aminomethane]-HCl, pH 8.3, in a total volume of 50 μL. Reaction tubes were preheated to 96°C for 5 minutes, followed by successive rounds of 94°C for 45 seconds, 55°C for 30 seconds, and 72°C for 30 seconds for 30 cycles, with a final extension time of 10 minutes at 72°C. The ssDNA was isolated for direct sequence analysis using a magnetic bead purification system (Dynal, Lake Success, NY). Sequencing was performed using Sequenase Version 2.0 according to the manufacturer's instructions (Amersham Pharmacia Biotech). The reaction products were electrophoresed in an 8% denaturing acrylamide gel and exposed to film.

Table 1.

Primers for PCR amplification of αIIb29

ExonName*Antisense primer 5′→3′NameSense primer 5′→3′
B1A XTGCTGCTCTCTCCCAATACCCCAAC 1S CCTGTGGAGGAATCTGAA 
2 + 3 B3A XAGACTTGGGCTCCTCCTGGCCCCAG 2SII ACGGTGGTCTGTGAGGTGTCATTG 
B4A XCAAGCCGTCGCGAGTGGG 4S CAATCGGGGGCAGGGACAC 
5 + 6 6A GAAAATATCCGCAACTGGAG B5S XTCCCTTCACCCCTGGGCTGACCCCT 
B9A XTTGTCAGCCTGAGAACTGGGATAAG 7SII TTCTGGCGGCTATTATTTCTTAGG 
8 + 9 B9A XTTGTCAGCCTGAGAACTGGGATAAG 8/9SII CTCCGTTTTTCCATCTGCACAATG 
10 + 11 10/11AII GAGGGGCAGCTCTGGTAATTTG B10S XTCACCTGGAGTGGGAGGTTGCTTTG 
12 12S2 GAGAGCAAGGGTCGAGGAGAT B12A XCTGTTAACCCCTCTGCAGCAAGTAG 
13 B13A XCTTGGCACTTCCAGCGAATGTCCAA 13SII CACTTTGCACCCCTTTCCTA 
14 + 15 B15A XCTGAGGTCCCAGATCCTTTAAGGCC 14S2 CTGGGAAGATGAGATGAGGA 
16 B17A XCTCCCAGCCCTGCCAATCCCCTGCC 16SII GTGTCCTACCTCAGACCAAG 
17 B17A XCTCCCAGCCCTGCCAATCCCCTGCC 17SII CTCAGAAGCTATGTGAGTGGC 
18 B18A XTACATTGTGACTTGGCACTAACCCT 18S CAGGTGCCTACTGGCCAG 
19 + 20 B20A XAGCCAAGGCTCCAGTGCCTCCCAGG 19S CAAGCCCACTGTTTTCCT 
21 21A AGAACTATGTGGCTCTAA B21S XCAGACCTTCCAAGGGAGCTTAAATA 
22 B22A XCCTGGCCTCGAAAGACCCTTCTGTA 22S AGGCCACATTCAGGGCAG 
23 + 24 B24AII XAAGGTGGATGCTGAGGTGAAGACCA 23SII CCTAGAGGAAGTTCTTTCCCAGGTC 
25 B26AII XCAAGTGTCTTTCAGCTCACCCCAGA 25S GGTATTGGGGAGCCTCGC 
26 B26AII XCAAGTGTCTTTCAGCTCACCCCAGA 26SII CCTGTCAACCCTCTCAAGGTAAGAG 
27 B27A XCTCCCAGAGCAAAGTGGTCCCGGCC 27S CCTTCTGCGTTGGGTCCT 
28 B28A XCTTTTCTGGCTGGGCACTGACTGGG 28SII ATTAGGTCAGAGGCAGGGCTTC 
29 29AII TGGTCCCTGGATTACCCACTTG B29S XTGTGAAAGGCAGGTGTCAAGGTGAC 
30 B30A XCAATGGAACAGCTCCAACCCAAAGC 30S CTGCGCTGGTCCAGGGAG 
ExonName*Antisense primer 5′→3′NameSense primer 5′→3′
B1A XTGCTGCTCTCTCCCAATACCCCAAC 1S CCTGTGGAGGAATCTGAA 
2 + 3 B3A XAGACTTGGGCTCCTCCTGGCCCCAG 2SII ACGGTGGTCTGTGAGGTGTCATTG 
B4A XCAAGCCGTCGCGAGTGGG 4S CAATCGGGGGCAGGGACAC 
5 + 6 6A GAAAATATCCGCAACTGGAG B5S XTCCCTTCACCCCTGGGCTGACCCCT 
B9A XTTGTCAGCCTGAGAACTGGGATAAG 7SII TTCTGGCGGCTATTATTTCTTAGG 
8 + 9 B9A XTTGTCAGCCTGAGAACTGGGATAAG 8/9SII CTCCGTTTTTCCATCTGCACAATG 
10 + 11 10/11AII GAGGGGCAGCTCTGGTAATTTG B10S XTCACCTGGAGTGGGAGGTTGCTTTG 
12 12S2 GAGAGCAAGGGTCGAGGAGAT B12A XCTGTTAACCCCTCTGCAGCAAGTAG 
13 B13A XCTTGGCACTTCCAGCGAATGTCCAA 13SII CACTTTGCACCCCTTTCCTA 
14 + 15 B15A XCTGAGGTCCCAGATCCTTTAAGGCC 14S2 CTGGGAAGATGAGATGAGGA 
16 B17A XCTCCCAGCCCTGCCAATCCCCTGCC 16SII GTGTCCTACCTCAGACCAAG 
17 B17A XCTCCCAGCCCTGCCAATCCCCTGCC 17SII CTCAGAAGCTATGTGAGTGGC 
18 B18A XTACATTGTGACTTGGCACTAACCCT 18S CAGGTGCCTACTGGCCAG 
19 + 20 B20A XAGCCAAGGCTCCAGTGCCTCCCAGG 19S CAAGCCCACTGTTTTCCT 
21 21A AGAACTATGTGGCTCTAA B21S XCAGACCTTCCAAGGGAGCTTAAATA 
22 B22A XCCTGGCCTCGAAAGACCCTTCTGTA 22S AGGCCACATTCAGGGCAG 
23 + 24 B24AII XAAGGTGGATGCTGAGGTGAAGACCA 23SII CCTAGAGGAAGTTCTTTCCCAGGTC 
25 B26AII XCAAGTGTCTTTCAGCTCACCCCAGA 25S GGTATTGGGGAGCCTCGC 
26 B26AII XCAAGTGTCTTTCAGCTCACCCCAGA 26SII CCTGTCAACCCTCTCAAGGTAAGAG 
27 B27A XCTCCCAGAGCAAAGTGGTCCCGGCC 27S CCTTCTGCGTTGGGTCCT 
28 B28A XCTTTTCTGGCTGGGCACTGACTGGG 28SII ATTAGGTCAGAGGCAGGGCTTC 
29 29AII TGGTCCCTGGATTACCCACTTG B29S XTGTGAAAGGCAGGTGTCAAGGTGAC 
30 B30A XCAATGGAACAGCTCCAACCCAAAGC 30S CTGCGCTGGTCCAGGGAG 
*

B indicates biotinylated.

X, biotin.

Table 2.

Primers for sequencing αIIb

ExonNameSequence primer 5′→3′
1S2 GGGAAGGAGGAGGAGCTG 
2 + 3 2S CTGGGATACGCTGGAATC  
 3S GGGCTTCAGCGCCCCAC 
4S2 GGCCAGGAGGAGCCCAAGTCT 
5 + 6 5A CTGGAAGGGAAGTCCTGAGG 
 5/6A CAAAGCGGTCTCCTTCGG  
7S CGTGCCCATCCGTACACC 
8 + 9 8/9SII CTCCGTTTTTCCATCTGCACAATG 
 9S CTGGAAAAGACTAATTTG 
10 + 11 10A TATTCTGAAGTCTCAGTTCC 
 10/11A CAACTGGGTAGGGGTGGG 
12 12S CCCTGGTCCAGTCCCATG  
 12SII TGTTCCTGCAGCCGCGAG 
13 13S CAATCAGCCACTTCCTTT 
14 + 15 14/15S CCCCATACCCTAATCGCC 
 15S AGGCCAGGAGGAGCCACA  
16 16S3 GTGAGCTGGTGAGGAGGC 
17 17S ACTCCCCCGGAGGCTGGCCAG 
 IIbL CTAAATGCCGAGCTGCAGCTG 
18 18S CAGGTGCCTACTGGCCAG 
19 + 20 19S2 GTAATCCCTAAACCTCACACA 
 20SII CTTTCTGCCTATCATACCTGC 
21 21A2 AATCTGGTTATTCATGAG 
22 22S2 TCCTAAGTGGGGCACTTG 
23 + 24 23S3 AAAGTCACTGGGCTGGTG 
 24S2 CTCACAGGCCAATCAGGG  
25 25S3 TGGCTGGGGTGAGCGGG 
26 26S CCAACCACCGGGGCACCT 
27 27S3 GGGTGGGGGATGATGGGGTG 
28 28S CGGGTGTGGGACCTGGAC 
29 29A AGGGCAGAGCCAAGCCTGTG 
30 30S2 AGCATACTTCCTCACATGTGC 
ExonNameSequence primer 5′→3′
1S2 GGGAAGGAGGAGGAGCTG 
2 + 3 2S CTGGGATACGCTGGAATC  
 3S GGGCTTCAGCGCCCCAC 
4S2 GGCCAGGAGGAGCCCAAGTCT 
5 + 6 5A CTGGAAGGGAAGTCCTGAGG 
 5/6A CAAAGCGGTCTCCTTCGG  
7S CGTGCCCATCCGTACACC 
8 + 9 8/9SII CTCCGTTTTTCCATCTGCACAATG 
 9S CTGGAAAAGACTAATTTG 
10 + 11 10A TATTCTGAAGTCTCAGTTCC 
 10/11A CAACTGGGTAGGGGTGGG 
12 12S CCCTGGTCCAGTCCCATG  
 12SII TGTTCCTGCAGCCGCGAG 
13 13S CAATCAGCCACTTCCTTT 
14 + 15 14/15S CCCCATACCCTAATCGCC 
 15S AGGCCAGGAGGAGCCACA  
16 16S3 GTGAGCTGGTGAGGAGGC 
17 17S ACTCCCCCGGAGGCTGGCCAG 
 IIbL CTAAATGCCGAGCTGCAGCTG 
18 18S CAGGTGCCTACTGGCCAG 
19 + 20 19S2 GTAATCCCTAAACCTCACACA 
 20SII CTTTCTGCCTATCATACCTGC 
21 21A2 AATCTGGTTATTCATGAG 
22 22S2 TCCTAAGTGGGGCACTTG 
23 + 24 23S3 AAAGTCACTGGGCTGGTG 
 24S2 CTCACAGGCCAATCAGGG  
25 25S3 TGGCTGGGGTGAGCGGG 
26 26S CCAACCACCGGGGCACCT 
27 27S3 GGGTGGGGGATGATGGGGTG 
28 28S CGGGTGTGGGACCTGGAC 
29 29A AGGGCAGAGCCAAGCCTGTG 
30 30S2 AGCATACTTCCTCACATGTGC 

Mutagenesis

Mutant αIIb cDNA constructs were generated using the splice by overlap extension PCR method as previously described.25The overlapping sense and antisense oligonucleotide primers used for the synthesis of the Val298Phe (985G>T) mutation were 5′CTGTCACTGACTTCAACGG3′ (sense) and 5′GTTGAAGTCAGTGACAGCC3′ (antisense) and the overlapping primers used for the Ile374Thr (1214T>C) mutation were 5′TGACACTGCAGTGGCTGC3′ (sense) and 5′CTGCAGTGTCATTGTAGCC3′ (antisense). The nucleotide substitutions are underlined. Control αIIb cDNA in the pcDNA3 mammalian cell expression vector (Invitrogen/Novex, Carlsbad, CA) was used as a template. The final PCR fragments carrying the mutations were ligated into the TA vector (Invitrogen) per the manufacturer's instructions for sequence analysis to confirm the nucleotide substitution and identify any PCR artifacts. The TA vectors containing the PCR fragments were digested with Pml-1 and Cla-1 (Roche Molecular Biochemicals, Indianapolis, IN) for ligation of the 600-bp fragments into control pcDNA3/αIIb vectors in which the same fragments were removed. Maxi-preparations (Qiagen, Valencia, CA) of the mutant αIIb/pcDNA3 cDNA constructs were performed for transfection and expression in mammalian cells.

Cell transfection and flow cytometry

Control and mutant αIIbβ3 receptors were expressed in human 293T cells. For transfection, cells were grown to 80% confluency in 100-mm tissue culture dishes. Control or mutant αIIb/pcDNA3 and β3/pcDNA3 cDNA constructs (6-8 μg each) were added with Lipofectamine according to the manufacturer's instructions (Gibco-BRL Life Technologies, Grand Island, NY). After 24 hours, cells from each dish were replated into 2 dishes. After 48 hours, cells (4 × 105/sample) were incubated with primary antibody for 30 minutes on ice followed by fluorescein isothiocyanate (FITC)-labeled secondary antibody for 30 minutes on ice. Cells were washed, resuspended in phosphate-buffered saline (PBS) with 2% fetal bovine serum (FBS), and analyzed by flow cytometry using a FACScan flow cytometer (Becton Dickinson, Mountain View, CA) with LYSYS II software (Becton Dickinson). Background controls were cells incubated with secondary FITC-labeled antibody alone. Transfection efficiencies were monitored by determining the levels of β3 expressed as αVβ3 with the small amount of αV constitutively present in the 293T cells. In all experiments, the levels of αVβ3 expression were within 9% of control levels (means ± SDs of 3 experiments).

Immunoprecipitation and immunoblot analyses

At 48 hours after transfection, cells were lysed in buffer (50 mM Tris-HCl, pH 7.5) containing 1% Triton X-100, 10 mM N-ethylmaleimide (NEM), and protease inhibitors (0.025 μg/mL Pefabloc, 20 μM leupeptin, 10 μg/mL E64, 5 μg/mL pepstatin; Roche Molecular Biochemicals) for 30 minutes on ice. Lysates were centrifuged at 10 000g for 30 minutes at 4°C and supernatants were precleared with protein A- or G-Sepharose (Amersham Pharmacia Biotech) at 4°C for 30 minutes. Total protein was quantified using the bicinchoninic acid (BCA) detection method (Pierce, Rockford, IL). Equivalent amounts of protein (400 μg) were incubated with the murine antihuman αIIb mAbs B1B530 31 (provided by Dr M. Poncz, University of Pennsylvania, Philadelphia) and M-148 (Santa Cruz Biotechnology, Santa Cruz, CA) for 18 hours at 4°C. Protein G-Sepharose was added and incubated for 1.0 hours at 4°C. The Sepharose-antibody complexes were washed twice with lysis buffer containing 500 mM NaCl. The immunoprecipitates were released from the Sepharose beads by incubation in SDS sample buffer and electrophoresed under reducing conditions. The separated proteins were transferred onto PVDF membranes and immunoblotted with the murine antihuman αIIb mAb PMI-1. Secondary labeling was with an HRP-conjugated rabbit antimouse κ light chain–specific antibody (Jackson Immunoresearch Laboratories) and membranes were developed using the enhanced chemiluminescence (ECL) method (Amersham Pharmacia Biotech).

Pulse-chase analysis

The levels of αIIb and β3 subunits in 293T transfected cells (36 hours) were determined by immunoprecipitation of whole cell lysates using equivalent trichloroacetic acid (TCA) precipitable counts (about 1.5 × 106 counts/sample). Cells (5 × 105/60 mm tissue culture well; 2 wells/group) were incubated in methionine/cysteine-free medium for 30 minutes, labeled with 35S-methionine/cysteine-containing medium (300 μCi/well [11.1 MBq/well]) for 15 minutes, and chased with fresh medium containing unlabeled methionine and cysteine (1 mg/mL each). Cells were harvested at 0-, 2-, 4-, 8-, and 24-hour time points and immunoprecipitations were performed, as described (see “Immunoprecipitation and immunoblot analyses”), using the αIIb-specific mAbs B1B530,31 and M-148 (Santa Cruz Biotechnology) and the β3-specific mAb AP332 (provided by Dr P. Newman, Blood Center S.E. Wisconsin, Milwaukee, WI; 4 μg each mAb/sample). Samples (reduced) were subjected to SDS-PAGE (7.5% gel) and the dried gels were exposed to film.

Molecular modeling

The structure of the αIIb β-propeller was modeled using the coordinates from the crystal structure of αV obtained from the Brookhaven Protein Database, PDB entry 1JV2.13Sequences were aligned using the Homology module of InsightII (Accelrys, San Diego, CA). The αV and αIIb propeller regions (residues 1-439 and 1-451, respectively) share 68% sequence similarity. The regions of highest homology are the calcium-binding domains and the novel “cage” motif residues immediately preceding them; these regions share more than 80% sequence similarity. The regions of poorest homology are the loops representing the upper surface of the second and third propeller blades. Coordinates were assigned to the αIIb β-propeller using the Homology module of InsightII. Where the sequences of αV and αIIb were identical, coordinates were simply assigned. Most of the nonhomologous regions were short (3-5 residue) loops. For each of these segments, a minimum of 20 short loop structures was generated that included at least 4 homologous residues flanking the loop at each end. Loops were chosen for the model that had the lowest energy and best superposition with the flanking residues whose coordinates had already been assigned. The 3 remaining nonhomologous regions were 3 larger loops, namely the 4-1 and 2-3 loops of blade 2 and the 4-1 loop of blade 3; because these loops are larger, more loop structures were generated (a minimum of 50) with at least 6 flanking residues on each end. Because these last 3 loops are above the propeller and thus furthest away from the calcium-binding domains, no further structural refinement was performed. Energy minimization was carried out on this final model in successive steps using InsightII. First, the splicing sites between the homologous regions and nonhomologous loops were energy minimized using the steepest descent method with a force constant to close the gaps and backbone angle constraints to conserve appropriate side-chain orientation. Then the inserted loops themselves were minimized, also using the steepest descent method. After this step, the CHARMM force field was used for final energy minimization using the Adopted Basis Newton-Raphson method.33 For evaluation of mutational defects, the individual amino acids were changed in the αIIb β-propeller model and energy was minimized again with the Adopted Basis Newton-Raphson method using CHARMM. Two sets of electrostatic potentials were calculated using CHARMM, one set using a constant dielectric and another set using a distance-dependent dielectric. All calculations were carried out in vacuo.

Platelet surface receptor and immunoblot analyses

Patient M.

To assess the surface expression of αIIbβ3 and αVβ3 receptors on the patient's platelets, radiolabeled antibody-binding studies were performed. The bindings of the anti-GPIbα mAb 6D1 to the platelets of patient M, his father, and his mother were 151%, 119%, and 93%, respectively, of the control value (Table3). The bindings of antibodies 10E5 (anti-αIIbβ3) and c7E3 Fab (anti-αIIbβ3 + αVβ3) to the platelets of patient M were 6% and 3% of normal, respectively. The binding of these antibodies to the platelets of the patient's parents ranged from 39% to 67% of normal. The binding of antibody LM609 (anti-αVβ3) to the platelets of patient M, his father, and his mother was 114%, 78%, and 113% of normal, respectively. The reduced binding of antibodies to αIIbβ3 and the normal/increased binding of antibodies to αVβ3 indicate an abnormality in αIIb.

Table 3.

Platelet surface receptors

Family members6D13-150anti-GPIb10E5 anti-αIIbβ37E3
anti-αIIbβ3 + αvβ3
LM609 anti-αvβ3
Patient M 151 117  
Father 119 58 67 78 
Mother 93 39 52 113  
Patient C 125 130  
Father 117 65 
Mother 92 54 56 100 
Sibling-1 109 108 
Sibling-2 121 10 125 
Family members6D13-150anti-GPIb10E5 anti-αIIbβ37E3
anti-αIIbβ3 + αvβ3
LM609 anti-αvβ3
Patient M 151 117  
Father 119 58 67 78 
Mother 93 39 52 113  
Patient C 125 130  
Father 117 65 
Mother 92 54 56 100 
Sibling-1 109 108 
Sibling-2 121 10 125 
F3-150

Expressed as percent of normal.

By immunoblot analysis, both αIIb and β3 subunits were detected in the patient's platelet lysates, but at reduced levels compared to a healthy control and samples from both parents (Figure1A). Mature αIIb subunits were detected, indicating normal processing of αIIb.

Fig. 1.

Immunoblots of platelet αIIb and β3 for patients M and C.

Platelets were solubilized in SDS, electrophoresed into a 7% polyacrylamide gel under reduced (αIIb) and nonreduced (β3) conditions, and electrotransferred to PVDF membranes. Equal amounts of protein were electrophoresed as judged by the staining of the gel after electrophoresis for platelet myosin heavy chain (Mr about 200 000). Membranes analyzed for αIIb were incubated with the mAb PMI-1, and membranes analyzed for β3 were incubated with the mAb 7H2.28 (A) Samples from patient M and his mother and father. (B) Samples from patient C and his 2 siblings.

Fig. 1.

Immunoblots of platelet αIIb and β3 for patients M and C.

Platelets were solubilized in SDS, electrophoresed into a 7% polyacrylamide gel under reduced (αIIb) and nonreduced (β3) conditions, and electrotransferred to PVDF membranes. Equal amounts of protein were electrophoresed as judged by the staining of the gel after electrophoresis for platelet myosin heavy chain (Mr about 200 000). Membranes analyzed for αIIb were incubated with the mAb PMI-1, and membranes analyzed for β3 were incubated with the mAb 7H2.28 (A) Samples from patient M and his mother and father. (B) Samples from patient C and his 2 siblings.

Close modal

Patient C.

To assess the surface expression of αIIbβ3 and αVβ3 receptors on the platelets of patient C, the same radiolabeled antibody-binding studies were performed. The bindings of the anti-GPIbα mAb 6D1 to the platelets of the patient, his father, mother, and 2 siblings were 125%, 117%, 92%, 109%, and 121%, respectively, of the control value (Table 3). The bindings of antibodies 10E5 (anti-αIIbβ3) and c7E3 Fab (anti-αIIbβ3 + αVβ3) to the platelets of patient C were 7% and 8% of normal. Interestingly, the binding of antibodies 10E5 and 7E3 to the platelets of the patient's father and 2 siblings was also 10% or less of normal, whereas the binding of these antibodies to the platelets of the patient's mother were 54% and 56% of normal, respectively. The binding of antibody LM609 (anti-αVβ3) to the platelets of the patient and his family members was normal. These data are consistent with abnormalities in αIIb in the patient, his father, and 2 siblings.

By immunoblot analysis, it was found that the platelets of the patient and his 2 siblings contained both αIIb and β3, but at reduced levels compared with a healthy control (Figure 1B). In all samples, mature αIIb subunits were present, suggesting that pro-αIIbβ3 complexes did form and that pro-αIIb was processed during maturation of the receptor complex.

Mutation identification for patients M and C

Direct sequence analyses of the genes encoding αIIb were performed on DNA isolated from leukocytes obtained from both patients and family members. Both patients are compound heterozygotes and the relative locations of each of their mutations is shown in a ribbon diagram of αV (Figure 2). Patient M inherited a Val298Phe missense mutation from his mother and a Tyr380X nonsense mutation from his father. The Val298Phe mutation, located in the second calcium-binding domain (propeller blade 5), was created by a G>T nucleotide substitution at position 985 of the pro-αIIb sequence encoded by exon 11. The Tyr380X mutation, located between the third and fourth calcium-binding domains, was created by an adenine nucleotide insertion at position 1233 of the pro-αIIb sequence encoded by exon 13. This insertion creates a TAA stop codon at amino acid Tyr380. Patient C inherited an Ile374Thr missense mutation from his mother and a Cys674Arg mutation from his father. The Ile374Thr mutation, located in the third calcium-binding domain (blade 6), was created by a T>C nucleotide substitution at position 1214 of the pro-αIIb sequence encoded by exon 13. The Cys674Arg mutation was created by a T>C nucleotide substitution at position 2113 of the pro-αIIb sequence encoded by exon 21. Sequence analyses of DNA from the father and 2 siblings of patient C showed that his father was homozygous for the Cys674Arg missense mutation and both siblings were compound heterozygous for the Cys674Arg and Ile374Thr missense mutations (data not shown).

Fig. 2.

Ribbon diagram of the αV subunit showing the relative locations of the αIIb mutations of patients M and C.

The αIIb and αV subunits share 40% sequence homology. This ribbon diagram of αV shows the relative positions of the 4 αIIb mutations, which are indicated by spheres (missense mutation) or a block (nonsense mutation) centered on the amino acid α-carbons (red and underlined for patient M, black for patient C). The β-propeller blades are designated W1-W7; the calcium atoms are shown in yellow. Three mutations lie within the β-propeller domain, blades W5 and W6, and the fourth is within the calf-1 domain. This image was generated with MOLMOL36 from the PDB file 1JV2.13 

Fig. 2.

Ribbon diagram of the αV subunit showing the relative locations of the αIIb mutations of patients M and C.

The αIIb and αV subunits share 40% sequence homology. This ribbon diagram of αV shows the relative positions of the 4 αIIb mutations, which are indicated by spheres (missense mutation) or a block (nonsense mutation) centered on the amino acid α-carbons (red and underlined for patient M, black for patient C). The β-propeller blades are designated W1-W7; the calcium atoms are shown in yellow. Three mutations lie within the β-propeller domain, blades W5 and W6, and the fourth is within the calf-1 domain. This image was generated with MOLMOL36 from the PDB file 1JV2.13 

Close modal

The Val298Phe mutation of patient M and the Ile374Thr mutation of patient C are the first to be reported within the second and third calcium-binding domains of the αIIb subunit. The other 2 mutations were not further characterized. The Tyr380X mutation in patient M presumably results in a truncated protein of about 42 kDa. Because the anti-αIIb mAb we used, PMI-1, recognizes an epitope distal to this region of αIIb,34 we would not detect such a fragment; thus, we are uncertain as to the biosynthesis and stability of such a fragment. The Cys674Arg mutation in patient C has been characterized in another patient with Glanzmann thrombasthenia and was shown to affect receptor biogenesis, resulting in about 10% of normal levels of surface expression.35 

Expression of mutant αIIbβ3 receptors in mammalian cells

Mutant receptor expression on the cell surface of transfected 293T cells was very low. Thus, only 13% ± 5% of cells expressing the αIIbVal298Phe mutation were positive by flow cytometry using the anti-αIIbβ3 mAb 10E5, and only 5% ± 3% of cells expressing the αIIbIle374Thr mutation were positive. In sharp contrast, 46% ± 12% of cells transfected with the normal receptors were positive by flow cytometry (data not shown).

To analyze the levels of pro-αIIb subunits expressed in 293T cells transfected with normal and mutant αIIbβ3 receptors, protein analyses were performed. Whole cell lysates were immunoprecipitated using anti-αIIb mAbs that recognize pro-αIIb and mature αIIb subunits. To identify mature αIIb subunits, the samples were electrophoresed under reduced conditions and immunoblotted with an anti-αIIb mAb (Figure 3). The majority of αIIb subunits in cells expressing normal αIIbβ3 receptors were processed to mature αIIb. In cells expressing either the Val298Phe or the Ile374Thr αIIb mutations, αIIb expression was dramatically reduced and only pro-αIIb subunits were detected. Because surface expression of both mutants was very low, as judged by flow cytometry, we infer that the proteins seen on immunoblot most likely represent defective αIIb subunits that are retained in the cell.

Fig. 3.

Immunoblot for αIIb of 293T cells transfected with mutant αIIbβ3 receptors.

Cells were solubilized in Triton X-100, electrophoresed into a 7% polyacrylamide gel under reduced conditions, and electrotransferred to PVDF membranes. Equal amounts of protein (150 μg), as determined by the BCA assay, were loaded per lane. The membrane was analyzed for αIIb using the mAb PMI-1. (A) Schematic diagram showing the processing and molecular weights of pro-αIIb in the endoplasmic reticulum and of mature αIIb in the Golgi. (B) Immunoblot of αIIb showing pro-αIIb and mature forms of control and mutant subunits.

Fig. 3.

Immunoblot for αIIb of 293T cells transfected with mutant αIIbβ3 receptors.

Cells were solubilized in Triton X-100, electrophoresed into a 7% polyacrylamide gel under reduced conditions, and electrotransferred to PVDF membranes. Equal amounts of protein (150 μg), as determined by the BCA assay, were loaded per lane. The membrane was analyzed for αIIb using the mAb PMI-1. (A) Schematic diagram showing the processing and molecular weights of pro-αIIb in the endoplasmic reticulum and of mature αIIb in the Golgi. (B) Immunoblot of αIIb showing pro-αIIb and mature forms of control and mutant subunits.

Close modal

Pulse-chase analyses were performed to assess the mechanisms responsible for the reduced levels of mutant αIIb (Figure4). Cell lysates were immunoprecipitated using anti-αIIb mAbs that recognize pro-αIIb and mature αIIb subunits. Cells expressing normal αIIbβ3 receptors show a normal maturation pattern. At time 0, only pro-αIIb and trace amounts of β3 subunits are detectable. By 2 hours, mature αIIb heavy-chain subunits are detectable, showing that pro-αIIb subunits have undergone processing and cleavage to form heavy and light chains. By 24 hours, only mature αIIbβ3-receptor complexes are detectable. The same analyses were performed on cells expressing αIIbβ3 receptors containing the Val298Phe and Ile374Thr mutations. In both cases, only pro-αIIb subunits were detected, and only at the early time points, suggesting that they were retained in the endoplasmic reticulum and subsequently degraded.

Fig. 4.

Pulse-chase analysis of transfected cells expressing control and mutant αIIbβ3 receptors.

Cells were cotransfected with cDNA constructs expressing control or mutant (Val298Phe and Ile374Thr) αIIb and control β3 subunits for 36 hours. Following preincubation in methionine/cysteine-free medium, cells were labeled with 35S-methionine/cysteine (300 μCi/well [11.1 MBq]) containing medium for 15 minutes and chased in medium containing methionine and cysteine (1 mg/mL each). Cells were harvested at the indicated time points. Using equivalent TCA precipitable counts (about 1.5 × 106 counts/sample), cell lysates were immunoprecipitated using a combination of αIIb-specific mAbs, B1B530 31 and M-148 (Santa Cruz Biotechnology; 4 μg each/sample) that recognize pro-αIIb and mature αIIb subunits. Samples were electrophoresed under reduced conditions and dried gels were exposed to film. Bands representing pro-αIIb, mature αIIb, and β3 are shown by arrows.

Fig. 4.

Pulse-chase analysis of transfected cells expressing control and mutant αIIbβ3 receptors.

Cells were cotransfected with cDNA constructs expressing control or mutant (Val298Phe and Ile374Thr) αIIb and control β3 subunits for 36 hours. Following preincubation in methionine/cysteine-free medium, cells were labeled with 35S-methionine/cysteine (300 μCi/well [11.1 MBq]) containing medium for 15 minutes and chased in medium containing methionine and cysteine (1 mg/mL each). Cells were harvested at the indicated time points. Using equivalent TCA precipitable counts (about 1.5 × 106 counts/sample), cell lysates were immunoprecipitated using a combination of αIIb-specific mAbs, B1B530 31 and M-148 (Santa Cruz Biotechnology; 4 μg each/sample) that recognize pro-αIIb and mature αIIb subunits. Samples were electrophoresed under reduced conditions and dried gels were exposed to film. Bands representing pro-αIIb, mature αIIb, and β3 are shown by arrows.

Close modal

Determining the role of the hydrophobic amino acids Val298 and Ile374 in αIIbβ3 biogenesis

Because the Val298Phe and Ile374Thr mutations disrupt biogenesis of the receptor complex, additional amino acid substitutions were analyzed at these sites. Figure 5A shows a schematic of an αIIb calcium-binding loop, including the 3 residues proximal to the loop (−3, −2, −1), and the relative locations of the patients' Val298Phe and Ile374Thr substitutions. The additional mutations that were created at these sites are shown in the boxes.

Fig. 5.

Effect of replacing residues Val298 and Ile374 with different amino acids on the maturation and processing of pro-αIIb to mature αIIb.

Cells were cotransfected with cDNA constructs expressing control or mutant αIIb and control β3 subunits for 36 hours. Whole cell lysates were prepared and immunoprecipitated with antibodies to αIIb (B1B5 and M-148). Immunoblots were performed with another antibody to αIIb (PMI-1). Bands representing pro-αIIb and mature αIIb are shown by arrows. (A) Schematic model of a calcium-binding loop showing residues numbered −3 to −1 and 1-12. The amino acid sequences of the second and third calcium-binding domains of αIIb are shown. The Val298 and Ile374 residues are underlined and the amino acids in the putative N-linked glycosylation site created by the Ile374Thr mutation are bracketed. The amino acid substitutions for residues Val298, Ile374, and Asn372 are shown in the boxes. (B) Immunoblot of cells expressing amino acid substitutions for residue Val298. (C) Immunoblot of cells expressing amino acid substitutions for residue Ile374. (D) Immunoblot of cells expressing amino acid substitutions for Ile374 and Asn372.

Fig. 5.

Effect of replacing residues Val298 and Ile374 with different amino acids on the maturation and processing of pro-αIIb to mature αIIb.

Cells were cotransfected with cDNA constructs expressing control or mutant αIIb and control β3 subunits for 36 hours. Whole cell lysates were prepared and immunoprecipitated with antibodies to αIIb (B1B5 and M-148). Immunoblots were performed with another antibody to αIIb (PMI-1). Bands representing pro-αIIb and mature αIIb are shown by arrows. (A) Schematic model of a calcium-binding loop showing residues numbered −3 to −1 and 1-12. The amino acid sequences of the second and third calcium-binding domains of αIIb are shown. The Val298 and Ile374 residues are underlined and the amino acids in the putative N-linked glycosylation site created by the Ile374Thr mutation are bracketed. The amino acid substitutions for residues Val298, Ile374, and Asn372 are shown in the boxes. (B) Immunoblot of cells expressing amino acid substitutions for residue Val298. (C) Immunoblot of cells expressing amino acid substitutions for residue Ile374. (D) Immunoblot of cells expressing amino acid substitutions for Ile374 and Asn372.

Close modal

Cells expressing receptors with either the Val298Phe mutation of patient M or the Val298Ala amino acid substitution show similar results, with greatly reduced levels of mature αIIb and a small amount of pro-αIIb (Figure 5B). In sharp contrast, cells expressing receptors containing the Val298Leu amino acid substitution had a level of mature αIIb similar to that of the control cells. These data show that replacing the branched-chain hydrophobic amino acid valine with the structurally similar leucine residue maintains αIIb maturation, but replacement with a smaller hydrophobic residue, such as alanine, or the bulkier hydrophobic phenylalanine, with its aromatic side chain, prevents αIIb maturation.

Cells expressing receptors with the Ile374Thr mutation of patient C had a markedly reduced level of pro-αIIb and virtually no mature αIIb (Figure 5C). Replacement of the branched-chain hydrophobic amino acid isoleucine with leucine or valine resulted in the expression of near-normal levels of mature αIIb subunits. Pro-αIIb was also detected in the Ile374Leu and Ile374Val mutants at levels greater than control, but the percentage of αIIb in the pro-αIIb form relative to mature was dramatically reduced when compared with the Ile374Thr mutation. Because isoleucine is the largest of the branched-chain amino acids, and because leucine and valine rescued αIIb maturation only partially, the large branched-side chain of isoleucine is likely to be a key structural requirement at this position.

The pro-αIIb subunits containing the Ile374Thr amino acid substitution migrated slightly slower in SDS-PAGE than the normal pro-αIIb subunits (Figure 5C-D), raising the possibility that the new N-linked glycosylation site created by the mutation (Figure 5A) is actually glycosylated. To explore this possibility further, 2 additional cDNA constructs were made: (1) Ile374Ser, which also creates an N-linked glycosylation site, and (2) Asn372Gln/Ile374Thr, which does not create an N-linked glycosylation site, but retains both the charge of the N and the patient's Ile374Thr mutation. Cells expressing receptors with the Ile374Ser substitution, like those with the patient's Ile374Thr substitution, showed only pro-αIIb subunits that migrated slower than control (Figure 5D). Cells expressing receptors with both the Ile374Thr mutation of patient C and the additional Asn372Gln substitution had pro-αIIb subunits that migrated normally, but no mature αIIb was detected. Because the elimination of the newly created N-linked glycosylation site did not restore maturation of the pro-αIIb subunit, these data show that the biosynthetic defect of patient C is due to the Ile374Thr amino acid substitution, and not additional glycosylation.

Surface expression of mutant receptors

To assess whether the amino acid substitutions that restored αIIb maturation also restored surface expression of αIIbβ3 complexes, flow cytometry was performed using the complex-dependent mAb, 10E5 (Figure 6). Receptors were detected on 33% of the control cells, whereas less than 10% of the cells transfected with Val298Phe or Ile374Thr bound 10E5. With the Val298Leu, Ile374Leu, and Ile374Val αIIb substitutions, all of which are branched-chain hydrophobic residues, αIIbβ3 was detected on 22%, 20%, and 31% of cells, respectively.

Fig. 6.

Effect of replacing αIIb residues Val298 and Ile374 with different amino acids on the surface expression of αIIbβ3 receptors.

Flow cytometry was performed on 293T cells cotransfected with αIIb constructs containing control, Val298 and Ile374, or substituted (Val298Phe, Val298Leu, Ile374Thr, Ile374Leu, Ile374Val) amino acid residues and a control β3 construct. Cells were incubated with the complex-dependent mAb, 10E5, then with FITC-labeled secondary antibody (shaded) and flow cytometry was performed. Background controls were cells incubated with secondary antibody alone (unshaded). Percentages indicate percent positive of gated cells.

Fig. 6.

Effect of replacing αIIb residues Val298 and Ile374 with different amino acids on the surface expression of αIIbβ3 receptors.

Flow cytometry was performed on 293T cells cotransfected with αIIb constructs containing control, Val298 and Ile374, or substituted (Val298Phe, Val298Leu, Ile374Thr, Ile374Leu, Ile374Val) amino acid residues and a control β3 construct. Cells were incubated with the complex-dependent mAb, 10E5, then with FITC-labeled secondary antibody (shaded) and flow cytometry was performed. Background controls were cells incubated with secondary antibody alone (unshaded). Percentages indicate percent positive of gated cells.

Close modal

The Val298Phe and Ile374Thr mutations adversely affect the electrostatic potentials of the calcium-binding domains as judged by a molecular model of the αIIb β-propeller

Because calcium binding is dependent on electrostatic interactions, we could assess the potential effects of the calcium-binding domain mutations on calcium binding in a molecular model by calculating their effects on the electrostatic potential at the calcium positions in the domains (Figure7). An increase in potential (more positive charge) would decrease the domain's ability to bind calcium, whereas a decrease in potential (more negative charge) would increase the domain's ability to bind calcium. The Val298Phe and Ile374Thr mutations resulted in striking increases in electrostatic potential at the second and third calcium positions, respectively, with little effect on the potentials at the other calcium positions. These data suggest that both mutations impair calcium binding. The Val298Ala mutation, which did not rescue the expression of αIIbβ3, resulted in increased electrostatic potentials at the second and third calcium positions, with a minimal decrease in electrostatic potential at the fourth calcium position. In contrast, the Val298Leu mutation, which rescued αIIbβ3 expression, not only prevented the increased electrostatic potential caused by the Val298Phe mutation at the second calcium position, but actually decreased the potential relative to control at the third and fourth calcium positions.

Fig. 7.

Effect of αIIb mutations on electrostatic potential.

The electrostatic potential was calculated at each of the 4 calcium positions in the αIIb β-propeller model. The Glanzmann thrombasthenia mutations Val298Phe and Ile374Thr, and the experimental mutations Val298Ala, Val298Leu, Ile374Leu, and Ile374Val were then inserted into the model and the electrostatic potentials were calculated. The relative change in electrostatic potential resulting from each mutation is depicted for each calcium position as a positive or negative bar. The normal electrostatic potential at each calcium position is arbitrarily set to 0. A positive change in electrostatic potential of more than 2 (the charge of calcium) would be expected to decrease the ability of calcium to bind, whereas a negative change in electrostatic potential would increase the ability of calcium to bind.

Fig. 7.

Effect of αIIb mutations on electrostatic potential.

The electrostatic potential was calculated at each of the 4 calcium positions in the αIIb β-propeller model. The Glanzmann thrombasthenia mutations Val298Phe and Ile374Thr, and the experimental mutations Val298Ala, Val298Leu, Ile374Leu, and Ile374Val were then inserted into the model and the electrostatic potentials were calculated. The relative change in electrostatic potential resulting from each mutation is depicted for each calcium position as a positive or negative bar. The normal electrostatic potential at each calcium position is arbitrarily set to 0. A positive change in electrostatic potential of more than 2 (the charge of calcium) would be expected to decrease the ability of calcium to bind, whereas a negative change in electrostatic potential would increase the ability of calcium to bind.

Close modal

The Ile374Leu mutation, which rescued αIIbβ3 expression, eliminated the increased electrostatic potential caused by the Ile374Thr mutation at the third calcium position, but it did increase the potential at the second calcium position. The Ile374Val mutation, which also rescued αIIbβ3 expression, partially reduced the increase in electrostatic potential at the third calcium position, and decreased the electrostatic potential at the fourth calcium position.

We have characterized 2 new αIIb calcium-binding domain mutations in patients with Glanzmann thrombasthenia and have identified structural elements within the calcium-binding domains that are essential for both maintaining an electrostatic potential conducive to calcium binding and for αIIbβ3-receptor biogenesis. Both the Val298Phe and the Ile374Thr mutations result in the expression of pro-αIIb subunits that are retained in the endoplasmic reticulum and degraded. Mutagenesis studies show that other branched-chain amino acids can substitute for valine at residue 298 (position 2 of the second calcium-binding domain), and for isoleucine at residue 374 (position 10 of the third calcium-binding domain). However, neither the larger phenylalanine nor the smaller alanine can substitute for valine at position 298, indicating stringent structural specifications for this position. The Ile374Thr mutation creates a new N-linked glycosylation site, but our data show that αIIbβ3 biogenesis is disrupted by the amino acid substitution, and not the additional glycosylation. Both mutations lie within clusters of highly conserved hydrophobic residues within the αIIb calcium-binding domains. Because the mutated residues are hydrophobic, their side chains are unable to directly participate in calcium coordination. However, calculations using a molecular model of αIIb show that both Glanzmann mutations dramatically affect the electrostatic potential in their respective calcium-binding domains, and that these changes are corrected by mutations that rescue αIIbβ3 expression. Together these data suggest that these 2 new mutations disrupt αIIb biogenesis by altering the structure of the calcium-binding domains and interfering with calcium binding, thereby disrupting a critical role played by the domains in biogenesis.

By using the molecular model of the αIIb β-propeller, previous findings regarding mutations within or near the calcium-binding domains may now be re-examined in light of their structural proximity to both the calcium-binding domains and to the cage motif. Figure 8 is a schematic of the β-propeller domain of αIIb showing the top of the β-propeller and the relative positions of the aromatic cage residues.

Fig. 8.

Mutations within the αIIb calcium-binding domains.

(Left) Schematic of the β-propeller domain of αIIb and αv showing the central cage motif. The blades are labeled W1 through W7. The cage motif comprises 2 concentric rings of predominantly aromatic residues, which line the upper, inner rim of the propeller core. Each blade contributes 2 residues to the cage structure, represented here by hexagons. (Right) Schematic of one blade of the αIIb β-propeller derived from molecular modeling, showing the relative locations of 7 Glanzmann thrombasthenia mutations that lie within blades W4-W7. The blade is viewed from the side, with the 2 cage residues indicated and the calcium-binding loop at the bottom. Starting from the cage residues, the 4 antiparallel β-strands of the blade form the legs of a “W.” Seven mutations reported to be in or near the calcium-binding domains (including the 2 from this study, underlined) are shown in their relative positions: Gly273Asp from W4; Val298Phe, Glu324Lys, and Arg327His from W5; Ile374Thr from W6; and Gly418Asp and deletion Val425/Asp426 from W7.7-11 

Fig. 8.

Mutations within the αIIb calcium-binding domains.

(Left) Schematic of the β-propeller domain of αIIb and αv showing the central cage motif. The blades are labeled W1 through W7. The cage motif comprises 2 concentric rings of predominantly aromatic residues, which line the upper, inner rim of the propeller core. Each blade contributes 2 residues to the cage structure, represented here by hexagons. (Right) Schematic of one blade of the αIIb β-propeller derived from molecular modeling, showing the relative locations of 7 Glanzmann thrombasthenia mutations that lie within blades W4-W7. The blade is viewed from the side, with the 2 cage residues indicated and the calcium-binding loop at the bottom. Starting from the cage residues, the 4 antiparallel β-strands of the blade form the legs of a “W.” Seven mutations reported to be in or near the calcium-binding domains (including the 2 from this study, underlined) are shown in their relative positions: Gly273Asp from W4; Val298Phe, Glu324Lys, and Arg327His from W5; Ile374Thr from W6; and Gly418Asp and deletion Val425/Asp426 from W7.7-11 

Close modal

The cage motif is comprised of 2 concentric rings of predominantly aromatic residues, which line the upper, inner rim of the propeller core. Each blade contributes 2 residues to the cage structure. The 4 antiparallel β strands of each blade form the legs of a “W.” The β sheet begins at the inner blade edge with the 2 aromatic cage residues. The first strand (A) feeds directly into the calcium-binding loop and the remaining 3 strands (B-D) form the β sheet and outer blade edge. Seven mutations reported to be in or near the calcium-binding domains (including the 2 from this study) are shown in their relative positions: Gly273Asp from W4; Val298Phe, Glu324Lys, and Arg327His from W5; Ile374Thr from W6; and Gly418Asp and deletion Val425/Asp426 from W7.7-11 

A molecular model of the αIIb β-propeller was constructed to analyze the structural effects of the calcium-binding domain mutations (Figure 9). The 2 mutations reported in this paper and the Gly273Asp7 mutation lie within the highly conserved hydrophobic regions flanking the calcium-binding β-hairpin loops. These presumably exert their effects by disrupting the β-hairpin loop stability. The fourth mutation, deletion Val425/Asp426,10 deletes the primary calcium-coordination residue, Asp426, and has been shown to disrupt calcium binding.37 The Gly418Asp8 mutation falls within the highly conserved cage structure and eliminates the universally conserved glycine hinge separating the inner and outer ring residues. This mutation was also shown to disrupt calcium binding.37 The finding that this relatively distant mutation (8 residues away and on the opposite propeller face) profoundly affects calcium binding is evidence of the structural intimacy between the calcium binding loops and the cage motif.

Fig. 9.

Model of the αIIb β-propeller showing calcium-binding mutations and cage residues.

A model of the αIIb β-propeller was generated as described in “Patients, materials, and methods.” (A) Top view of the propeller showing the 7 blades (W1-W7), the 4 calcium ions (yellow), and the locations of 7 reported calcium-binding domain mutations (black and cyan spheres; mutations identified in this study are cyan). (B) Side view of the propeller with the mutations labeled. (C) Blades W4-W7 are viewed from the side. The 2 critical cage residues are displayed. A sphere centered on the amino acid α-carbon identifies the positions of each calcium-binding domain mutation. This figure was generated with MOLMOL.36 

Fig. 9.

Model of the αIIb β-propeller showing calcium-binding mutations and cage residues.

A model of the αIIb β-propeller was generated as described in “Patients, materials, and methods.” (A) Top view of the propeller showing the 7 blades (W1-W7), the 4 calcium ions (yellow), and the locations of 7 reported calcium-binding domain mutations (black and cyan spheres; mutations identified in this study are cyan). (B) Side view of the propeller with the mutations labeled. (C) Blades W4-W7 are viewed from the side. The 2 critical cage residues are displayed. A sphere centered on the amino acid α-carbon identifies the positions of each calcium-binding domain mutation. This figure was generated with MOLMOL.36 

Close modal

Our calculations of electrostatic potential suggest that both the Val298Phe and Ile374Thr mutations disrupt calcium binding in their respective domains by increasing the local electrostatic potential. Conversely, the Val298Leu and both Ile374Leu and Ile374Val mutations reverse the electrostatic effects of the Val298Phe and Ile374Thr mutations, respectively. The αIIb and αV propeller regions share 68% homology, with more than 80% homology in the calcium-binding regions. Therefore, our model is likely to have the greatest accuracy in these regions. The major structural differences between αIIb and αV lie in the upper loops of W2 and W3: the 4-1 and 2-3 loops of blades W2 and the 4-1 loop of W3. Interestingly, these same loops are implicated in ligand binding.40 

The α-integrin calcium-binding domains have all of the structural characteristics of β-hairpin loops, consisting of a charged loop with a glycine hinge, flanked by groups of hydrophobic residues.15 Branched-chain hydrophobic residues are highly conserved at positions 2 and 10-12 in all 18 of the currently identified integrin α subunits.41-50 The β-hairpin loops play important roles in protein folding and stability, enhancing the folding rate and structural stability of entire β-sheet structures.16 The β-hairpin turns are stabilized by both hydrogen bonding between the strand backbones and by hydrophobic interactions among the flanking residues.51 The mutations at positions Val298 and Ile374 fall within the highly conserved clusters of hydrophobic residues flanking the αIIb calcium-binding domains, and thus it is likely that the mutations exert their effects by destabilizing the β-hairpin loops. Based on data from other systems,52 it is likely that in the calcium-rich lumen of the endoplasmic reticulum, nascent calcium-binding domains are likely to fold around the available calcium ions immediately upon translocation.53 Thus, the β-hairpin calcium-binding domains may be crucial for the proper folding of the entire β-propeller, which is the site of interaction between the α- and β-integrin subunits.

An intimate structural relationship is also apparent between the calcium-binding domains and the novel cage motif, which forms the central contact point between the 2 subunits. The cage structure is comprised of 2 concentric rings of aromatic residues encircling the top rim of the central propeller pore. Each propeller blade contributes 2 hydrophobic residues to each ring (Figure 8). Arg261 of the β3-A domain extends through the rings of aromatic residues and is captured by hydrophobic interactions with the aromatic residues.13Because the Val298Phe and Ile374Thr mutations do not introduce any changes in charge, the observed changes in electrostatic potential represent a subtle repositioning of the side chains in the surrounding regions, which includes the cage motif. Consequently, structural disruption of the calcium-binding loops could result in structural alterations of the cage motif that affect the conformation and stability of the αIIb-β3 interface. In support of this hypothesis is the observation that none of the α-β heterodimers containing the Val298Phe, Ile374Thr, Gly273Asp, Gly418Asp, or deletion Val425/Asp426 mutations were recognized by complex-dependent mAbs, even though they do not prevent coimmunoprecipitation of the α-β heterodimer by subunit-specific mAbs.7,8 10 This indicates that although these mutant αIIb subunits can form a complex with β3, the complexes are not in their native conformations.

Previously, the effects of 3 Glanzmann thrombasthenia mutations (Figures 8-9: Gly273Asp, Gly418Asp, deletion Val425/Asp426) on calcium binding were analyzed by terbium luminescence.37 Short polypeptides were generated that represented the individual αIIb calcium-binding domains with and without the mutations. Based on the techniques of Cierniewski,38 tyrosine and tryptophan residues were substituted at positions 7 and 11 of each of the calcium-binding domains in the peptides to enhance the luminescence energy of the bound terbium. The Gly418Asp and deletion Val425/Asp426 mutations both resulted in loss of terbium luminescence, reflecting loss of calcium binding. When these mutations were tested in longer peptides that comprised all 4 calcium-binding domains, they also abrogated calcium binding. No change in terbium luminescence was noted, however, in the Gly273Asp peptide, which was interpreted as indicating that the mutation did not result in defective calcium binding. This finding is contradictory to the findings of the present study, in that the Gly273Asp mutation inserts a charged residue into the hydrophobic cluster of residues flanking the first calcium-binding domain. Calculations based on our molecular model suggest that such a mutation would disrupt calcium binding. We believe, however, that our data and those regarding the Gly273Asp mutation can be reconciled based on 2 considerations.

First, the Gly273Asp mutant was only tested in the short peptide, and thus it was not subjected to the steric interactions that accompany the close packing in the propeller region. Second, the tyrosine to tryptophan substitution made at position 11 to enhance terbium luminescence may have affected the results. In both αV and our model of αIIb the hydrophobic residues at positions −1 and 11 in the β-hairpin calcium-binding loops are close enough to interact (Figure 5A). The Gly273Asp substitution places an aspartic acid at position −1, which would not be expected to interact with the tyrosine at position 11. However, aspartic acid can interact with the imino group of tryptophan.39 Thus, the tryptophan substitution may have inadvertently prevented the Gly273Asp mutation from disrupting cation binding.

In conclusion, through combining protein expression and mutagenesis studies with the newly available crystal structure data and molecular modeling, we have identified structural elements of the α-integrin calcium-binding domains that are essential for both calcium binding and αIIbβ3-receptor biogenesis. This study supports the hypothesis that the calcium-binding domains play an essential structural role in integrin biogenesis by facilitating the early folding process of αIIb and conferring stability to the cage motif during αIIbβ3-heterodimer formation.

We thank Drs Ginsberg, Poncz, and Newman for the generous supply of monoclonal antibodies. We are grateful to Drs Harel Weinstein, Ernest Mehler, and Mihaly Mezei in the Department of Physiology and Biophysics at the Mount Sinai School of Medicine, New York, NY, for the use of their computer facility and assistance with molecular modeling software.

Prepublished online as Blood First Edition Paper, November 7, 2002; DOI 10.1182/blood-2002-07-2266.

Supported in part by National Institutes of Health (NIH), National Heart, Lung and Blood Institute grant HL 19278 (B.S.C.); American Heart Association Heritage Affiliate Ilma F. Kern Foundation in honor of John Halperin, MD; The Charles Slaughter Foundation (D.L.F); and a fellowship from an Institutional National Research Service Award, National Heart, Lung and Blood Institute T32 HL07824-06 (to W.B.M.).

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.

1
George
 
JN
Caen
 
JP
Nurden
 
AT
Glanzmann's thrombasthenia: the spectrum of clinical disease.
Blood.
75
1990
1383
1395
2
French
 
DL
The molecular genetics of Glanzmann's thrombasthenia.
Platelets.
9
1998
5
20
3
Coller
 
BS
Anti-GPIIb/IIIa drugs: current strategies and future directions.
Thromb Haemost.
86
2001
427
443
4
Hynes
 
RO
Integrins: a family of cell surface receptors.
Cell.
48
1987
549
554
5
Duperray
 
A
Berthier
 
R
Chagnon
 
E
et al
Biosynthesis and processing of platelet GPIIb-IIIa in human megakaryocytes.
J Cell Biol.
104
1987
1665
1673
6
O'Toole
 
TE
Loftus
 
JC
Plow
 
EF
Glass
 
AA
Harper
 
JR
Ginsberg
 
MH
Efficient surface expression of platelet GPIIb-IIIa requires both subunits.
Blood.
74
1989
14
18
7
Poncz
 
M
Rifat
 
S
Coller
 
BS
et al
Glanzmann thrombasthenia secondary to a Gly273Asp mutation adjacent to the first calcium-binding domain of platelet glycoprotein IIb.
J Clin Invest.
93
1994
172
179
8
Wilcox
 
DA
Wautier
 
JL
Pidard
 
D
Newman
 
PJ
A single amino acid substitution flanking the fourth calcium binding domain of αIIb prevents maturation of the integrin αIIbβ3 complex.
J Biol Chem.
269
1994
4450
4457
9
Wilcox
 
DA
Paddock
 
CM
Lyman
 
S
Gill
 
JC
Newman
 
PJ
Glanzmann thrombasthenia resulting from a single amino acid substitution between the second and third calcium-binding domains of GPIIb.
J Clin Invest.
95
1995
1553
1560
10
Basani
 
RB
Vilaire
 
G
Shattil
 
SJ
Kolodziej
 
MA
Bennett
 
JS
Poncz
 
M
Glanzmann thrombasthenia due to a two amino acid deletion in the fourth calcium-binding domain of αIIb: demonstration of the importance of calcium-binding domains in the conformation of αIIbβ3.
Blood.
88
1996
167
173
11
Ferrer
 
M
Fernandez-Pinel
 
M
Gonzalez-Manchon
 
C
Gonzalez
 
J
Ayuso
 
MS
Parrilla
 
R
A mutant (Arg327His) GPIIb associated to thrombasthenia exerts a dominant negative effect in stably transfected CHO cells.
Thromb Haemost.
76
1996
292
301
12
Springer
 
TA
Folding of the N-terminal, ligand-binding region of integrin α-subunits into a β-propeller domain.
Proc Natl Acad Sci U S A.
94
1997
65
72
13
Xiong
 
J-P
Stehle
 
T
Diefenbach
 
B
et al
Crystal structure of the extracellular segment of integrin alphaVbeta3.
Science.
294
2001
339
345
14
Tuckwell
 
DS
Brass
 
A
Humphries
 
MJ
Homology modelling of integrin EF-hands. Evidence for widespread use of a conserved cation-binding site.
Biochem J.
285
1992
325
331
15
Springer
 
TA
Jing
 
H
Takagi
 
J
A novel Ca2+ binding beta hairpin loop better resembles integrin sequence motifs than the EF hand.
Cell.
102
2000
275
277
16
Eaton
 
WA
Munoz
 
V
Hagen
 
SJ
et al
Fast kinetics and mechanisms in protein folding.
Annu Rev Biophys Biomol Struct.
29
2000
327
359
17
Michelson
 
AD
Flow cytometric analysis of platelet surface glycoproteins: phenotypically distinct subpopulations of platelets in children with chronic myeloid leukemia.
J Lab Clin Med.
110
1987
346
354
18
Coller
 
BS
Seligsohn
 
U
Zivelin
 
A
Zwang
 
E
Lusky
 
A
Modan
 
M
Immunologic and biochemical characterization of homozygous and heterozygous Glanzmann thrombasthenia in the Iraqi-Jewish and Arab populations in Israel: comparison of techniques for carrier detection.
Br J Haematol.
62
1986
723
735
19
Coller
 
BS
Peerschke
 
EI
Scudder
 
LE
Sullivan
 
CA
Studies with a murine monoclonal antibody that abolishes ristocetin-induced binding of von Willebrand factor to platelets: additional evidence in support of GPIb as a platelet receptor for von Willebrand factor.
Blood.
61
1983
99
110
20
Coller
 
BS
Peerschke
 
EI
Scudder
 
LE
Sullivan
 
CA
A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds glycoproteins IIb and/or IIIa.
J Clin Invest.
72
1983
325
338
21
Coller
 
BS
A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex.
J Clin Invest.
76
1985
101
108
22
Knight
 
DM
Wagner
 
C
Jordan
 
R
et al
Humanizing the constant region of the 7E3 murine monoclonal Fab antibody fragment reduces the immunogenicity of the variable region in humans.
Mol Immunol.
32
1995
1271
1281
23
Cheresh
 
DA
Spiro
 
RC
Biosynthetic and functional properties of an arg-gly-asp-directed receptor involved in human melanoma cell attachment to vitronectin, fibrinogen, and von Willebrand factor.
J Biol Chem.
262
1987
17703
17711
24
Coller
 
BS
Seligsohn
 
U
Little
 
PA
Type I Glanzmann thrombasthenia patients from the Iraqi-Jewish and Arab populations in Israel can be differentiated by platelet glycoprotein IIIa immunoblot analysis.
Blood.
69
1987
1969
1703
25
Grimaldi
 
CM
Chen
 
FP
Scudder
 
LE
Coller
 
BS
French
 
DL
A Cys374Tyr homozygous mutation of platelet glycoprotein IIIa (β3) in a Chinese patient with Glanzmann's thrombasthenia.
Blood.
88
1996
1666
1675
26
Shadle
 
PJ
Ginsberg
 
MH
Plow
 
EF
Barondes
 
SH
Platelet-collagen adhesion: Inhibition by a monoclonal antibody that binds glycoprotein IIb.
J Cell Biol.
99
1984
2056
2060
27
Ginsberg
 
MH
Lightsey
 
A
Kunicki
 
TJ
Kaufmann
 
A
Marguerie
 
G
Plow
 
EF
Divalent cation regulation of the surface orientation of platelet membrane glycoprotein IIb. Correlation with fibrinogen binding function and definition of a novel variant of Glanzmann's thrombasthenia.
J Clin Invest.
78
1986
1103
1111
28
Kutok
 
JL
Coller
 
BS
Partial inhibition of platelet aggregation and fibrinogen binding by a murine monoclonal antibody to GPIIIa: requirement for antibody bivalency.
Thromb Haemost.
72
1994
964
972
29
Heidenreich
 
R
Eisman
 
R
Surrey
 
S
et al
Organization of the gene for platelet glycoprotein IIb.
Biochemistry.
29
1990
1232
1244
30
Silver
 
SM
McDonough
 
MM
Vilaire
 
G
Bennett
 
JS
The in vitro synthesis of polypeptides for the platelet membrane glycoproteins IIb and IIIa.
Blood.
69
1987
1031
1037
31
Poncz
 
M
Eisman
 
R
Heidenreich
 
R
et al
Structure of the platelet membrane glycoprotein IIb.
J Biol Chem.
262
1987
8476
8482
32
Newman
 
PJ
Allen
 
RW
Kahn
 
RA
Kunicki
 
TJ
Quantitation of membrane glycoprotein IIIa on intact human platelets using the monoclonal antibody, AP-3.
Blood.
65
1985
227
232
33
MacKerell
 
AD
Brooks
 
B
Brooks
 
CL
et al
CHARMM: The energy function and its parameterization with an overview of the program.
The Encyclopedia of Computational Chemistry.
Schleyer Pv
 
R
et al
1
1998
271
277
Wiley
Chichester, United Kingdom
34
Loftus
 
JC
Plow
 
EF
Frelinger
 
ALI
et al
Molecular cloning and chemical synthesis of a region of platelet glycoprotein IIb involved in adhesive function.
Proc Natl Acad Sci U S A.
84
1987
7114
7118
35
Gonzalez-Manchon
 
C
Fernandez-Pinel
 
M
Arias-Salgado
 
EG
et al
Molecular genetic analysis of a compound heterozygote for the glycoprotein (GP) IIb gene associated with Glanzmann's thrombasthenia: disruption of the 674-687 disulfide bridge in GPIIb prevents surface exposure of GPIIb-IIIa complexes.
Blood.
93
1999
866
875
36
Koradi
 
R
Billeter
 
M
Wuthrich
 
K
MOLMOL: a program for display and analysis of macromolecular structures.
J Mol Graph.
14
1996
51
55
37
Jackson
 
DE
Poncz
 
M
Holyst
 
MT
Newman
 
PJ
Inherited mutations within the calcium-binding sites of the integrin αIIb subunit (platelet glycoprotein IIb). Effects of the amino acid side chain and the amino acid position on cation binding.
Eur J Biochem.
240
1996
280
287
38
Cierniewski
 
C
Haas
 
T
Smith
 
J
Plow
 
E
Characterization of cation binding sequences in the platelet integrin GPIIb-IIIa (alpha IIb beta 3) by terbium luminescence.
Biochemistry.
33
1994
12238
12246
39
Brocchieri
 
L
Karlin
 
S
Geometry of interplanar residue contacts in protein structures.
Proc Natl Acad Sci U S A.
91
1994
9297
9301
40
Kamata
 
T
Tieu
 
KK
Irie
 
A
Springer
 
TA
Takada
 
Y
Amino acid residues in the alpha IIb subunit that are critical for ligand binding to integrin alpha IIbbeta 3 are clustered in the beta-propeller model.
J Biol Chem.
276
2001
44275
44283
41
Larson
 
RS
Corbi
 
AL
Berman
 
L
Springer
 
TA
Primary structure of the leukocyte function-associated molecule-1 alpha subunit: an integrin with an embedded domain defining a protein superfamily.
J Cell Biol.
108
1989
703
712
42
Tamura
 
RN
Rozzo
 
C
Starr
 
L
et al
Epithelial integrin alpha 6 beta 4: complete primary structure of alpha 6 and variant forms of beta 4.
J Cell Biol.
111
1990
1593
1604
43
Takada
 
Y
Murphy
 
E
Pil
 
P
Chen
 
C
Ginsberg
 
MH
Hemler
 
ME
Molecular cloning and expression of the cDNA for alpha 3 subunit of human alpha 3 beta 1 (VLA-3), an integrin receptor for fibronectin, laminin, and collagen.
J Cell Biol.
115
1991
257
266
44
Briesewitz
 
R
Epstein
 
MR
Marcantonio
 
EE
Expression of native and truncated forms of the human integrin alpha1 subunit.
J Biol Chem.
268
1993
2989
2996
45
Palmer
 
EL
Ruegg
 
C
Ferrando
 
R
Pytela
 
R
Sheppard
 
D
Sequence and tissue distribution of the integrin alpha 9 subunit, a novel partner of beta 1 that is widely distributed in epithelia and muscle.
J Cell Biol.
123
1993
1289
1297
46
Shaw
 
SK
Cepek
 
KL
Murphy
 
EA
Russell
 
GJ
Brenner
 
MB
Parker
 
CM
Molecular cloning of the human mucosal lymphocyte integrin alpha E subunit. Unusual structure and restricted RNA distribution.
J Biol Chem.
269
1994
6016
6025
47
Schnapp
 
LM
Breuss
 
JM
Ramos
 
DM
Sheppard
 
D
Pytela
 
R
Sequence and tissue distribution of the human integrin alpha 8 subunit: a beta 1-associated alpha subunit expressed in smooth muscle cells.
J Cell Sci.
108
1995
537
544
48
Hayashi
 
YK
Chou
 
FL
Engvall
 
E
et al
Mutations in the integrin alpha7 gene cause congenital myopathy.
Nat Genet.
19
1998
94
97
49
Lehnert
 
K
Ni
 
J
Leung
 
E
et al
The integrin alpha 10 subunit: expression pattern, partial gene structure, and chromosomal localization.
Cytogenet Cell Genet.
87
1999
238
244
50
Lehnert
 
K
Ni
 
J
Leung
 
E
et al
Cloning, sequence analysis, and chromosomal localization of the novel human integrin alpha11 subunit (ITGA11).
Genomics.
60
1999
179
187
51
Munoz
 
V
Thompson
 
PA
Hofrichter
 
J
Eaton
 
WA
Folding dynamics and mechanism of beta-hairpin formation.
Nature.
390
1997
196
199
52
Marsden
 
BJ
Hodges
 
RS
Sykes
 
BD
A 1H NMR determination of the solution conformation of a synthetic peptide analogue of calcium-binding site III of rabbit skeletal troponin C.
Biochemistry.
28
1989
8839
8847
53
Stevens
 
FJ
Argon
 
Y
Protein folding in the ER.
Semin Cell Dev Biol.
10
1999
443
454

Author notes

Deborah L. French, Box 1079 Hematology, Mount Sinai School of Medicine, 1 Gustave L. Levy Pl, New York, NY 10029; e-mail: debbie.french@mssm.edu.

Sign in via your Institution